- The report contains detailed information about Cubist Pharmaceuticals Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Cubist Pharmaceuticals Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Cubist Pharmaceuticals Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Cubist Pharmaceuticals Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Cubist Pharmaceuticals Inc. business.
About Cubist Pharmaceuticals Inc.
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
The company markets CUBICIN (daptomycin for injection), which is a once-daily, bactericidal, intravenous (I.V.) antibiotic with activity against certain Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (S. aureus), or MRSA, and, as of December 31, 2009, had been used in the treatment of approximately an estimated 880,000 patients in the U.S. CUBICIN is approved in the U.S. for the treatment of complicated skin and skin structure infections (cSSSI) caused by S. aureus, and certain other Gram-positive bacteria, and for S. aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis (RIE) caused by methicillin-susceptible and methicillin-resistant isolates.
In the European Union (EU), CUBICIN is approved for the treatment of complicated skin and soft tissue infections (cSSTI), where the presence of susceptible Gram-positive bacteria is confirmed or suspected and for RIE due to S. aureus bacteremia and S. aureus bacteremia associated with RIE or cSSTI. Novartis AG is marketing and selling CUBICIN in the EU. In addition to the EU, Novartis has rights to develop, market, and sell CUBICIN in Australia, New Zealand, India, and certain Central American, South American and the Middle East countries; AstraZeneca AB has rights to develop, market, and sell CUBICIN in China, as well as additional countries around the world; and Merck & Co., Inc. (Merck), through its wholly-owned subsidiary, Banyu Pharmaceutical Co., Ltd., has rights to develop, market and sell CUBICIN in Japan. Other international partners for CUBICIN include Medison Pharma, Ltd. for Israel, Sepracor, Inc. (Sepracor) for Canada, TTY BioPharm for Taiwan, and Kuhnil Pharma Co., Ltd. for Korea. Sepracor was acquired by Dainippon Sumitomo Pharma Co., Ltd. in October 2009.
The company has acquired and licensed technology from Eli Lilly and Company (Eli Lilly) related to the composition, manufacture, and use of daptomycin, the active ingredient in CUBICIN. It has a manufacturing and supply agreement with ACS Dobfar SpA (ACSD), pursuant to which ACSD manufactures and supplies the company active pharmaceutical ingredients for CUBICIN.
The company's competitors in the United States include Abbott Laboratories; Shionogi & Co., Ltd.; Pfizer, Inc. (Pfizer); King Pharmaceuticals, Inc.; Wyeth, wholly-owned subsidiary of Pfizer; Astellas Pharma US, Inc.; Theravance, Inc.; The Medicines Company; Forset Laboratories, Inc.; Teva Parenteral Medicines, Inc.; and Basilea Pharmaceutica AG.
The company promotes and supports MERREM I.V. (meropenem for injection) using its existing U.S. acute care sales and medical affairs organizations pursuant to a commercial services agreement that the company entered into with AstraZeneca Pharmaceuticals, LP (AstraZeneca). The company is obligated under the agreement to provide certain levels of support with respect to MERREM I.V., including requirements related to sales calls to physicians, specified priority of presentation of MERREM I.V. relative to other products, and a minimum number of MERREM I.V. sales representatives and clinical science directors. AstraZeneca provides marketing and other commercial support for MERREM I.V.
The company's competitors include Merck; Ortho-McNeil, a Johnson & Johnson company; and Ranbaxy Laboratories Limited.
The company has obtained a license for the development and commercialization in North America and Europe of the I.V. formulation of CB-500,929 for the prevention of blood loss during surgery pursuant to a license and collaboration agreement with Dyax Corp. (Dyax). The company is studying ecallantide initially in the reduction of blood loss in patients undergoing cardiac surgery using cardiopulmonary bypass, which includes coronary artery bypass graft (CABG) and heart valve repair and replacement p
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. CUBIST PHARMACEUTICALS INC. COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. CUBIST PHARMACEUTICALS INC. BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. CUBIST PHARMACEUTICALS INC. SWOT ANALYSIS
4. CUBIST PHARMACEUTICALS INC. FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. CUBIST PHARMACEUTICALS INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Cubist Pharmaceuticals Inc. Direct Competitors
5.2. Comparison of Cubist Pharmaceuticals Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Cubist Pharmaceuticals Inc. and Direct Competitors Stock Charts
5.4. Cubist Pharmaceuticals Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Cubist Pharmaceuticals Inc. Industry Position Analysis
6. CUBIST PHARMACEUTICALS INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. CUBIST PHARMACEUTICALS INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. CUBIST PHARMACEUTICALS INC. ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. CUBIST PHARMACEUTICALS INC. IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. CUBIST PHARMACEUTICALS INC. PORTER FIVE FORCES ANALYSIS2
12. CUBIST PHARMACEUTICALS INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Cubist Pharmaceuticals Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Cubist Pharmaceuticals Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Cubist Pharmaceuticals Inc. Major Shareholders
Cubist Pharmaceuticals Inc. History
Cubist Pharmaceuticals Inc. Products
Revenues by Segment
Revenues by Region
Cubist Pharmaceuticals Inc. Offices and Representations
Cubist Pharmaceuticals Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Cubist Pharmaceuticals Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Cubist Pharmaceuticals Inc. Capital Market Snapshot
Cubist Pharmaceuticals Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Cubist Pharmaceuticals Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Cubist Pharmaceuticals Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Cubist Pharmaceuticals Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Cubist Pharmaceuticals Inc. 1-year Stock Charts
Cubist Pharmaceuticals Inc. 5-year Stock Charts
Cubist Pharmaceuticals Inc. vs. Main Indexes 1-year Stock Chart
Cubist Pharmaceuticals Inc. vs. Direct Competitors 1-year Stock Charts
Cubist Pharmaceuticals Inc. Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?